Research Roundup


20191453 - idea concept with light bulbs and energy save bulb green background

Debbie Rigby rounds up the latest in research news

Efficacy and safety of nutrient supplements in the treatment of mental disorders

A meta‐review of meta‐analyses of randomized controlled trials of nutritional supplements in mental disorders has concluded the strongest evidence is for PUFAs (particularly as eicosapentaenoic acid) as an adjunctive treatment for depression. DHA or DHA‐predominant formulas do not appear to show any obvious benefit in major depression. The majority of nutritional supplements assessed did not significantly improve mental health outcomes beyond control conditions.

World Psychiatry 2019;18:308–324.

 

Patient Perceptions of Diabetes Guideline Frameworks for Individualizing Glycemic Targets

A survey of 818 USA adilts 65 years and older with type 2 diabetes do not place high importance on factors recommended by guidelines to individualize diabetes treatment, especially when deciding to stop use of diabetes medications. The authors concluded individualizing diabetes care in older adults will require effective communication regarding the benefits and consequences of making changes to treatment plans.

JAMA Intern Med. Published online September 16, 2019.

 

Long-term macrolide antibiotics for the treatment of bronchiectasis in adults

Bronchiectasis guidelines recommend long-term macrolide treatment (azithroycin, erythromycin) for patients with three or more exacerbations per year without Pseudomonas aeruginosa infection. A meta-analysis of 234 studies shows that long-term macrolide treatment significantly reduces the frequency of exacerbations in patients with bronchiectasis, with similar benefits observed in all subgroups based on patient characteristics.

Lancet Respiratory Medicine, published 9 August 2019.

 

The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults

A systematic review and meta-analysis of 16 randomised trials supports use of inhaled antibiotics (e.g. ciprofloxacin, aztreonam, tobramycin, colistin, gentamicin) in patients with bronchiectasis not due to cystic fibrosis. Inhaled antibiotics are well tolerated, reduce bacterial load, and achieve a small but statistically significant reduction in exacerbation frequency without clinically significant improvements in quality of life in patients with bronchiectasis and chronic respiratory tract infections.

Lancet Respiratory Medicine, published 9 August 2019.

Previous ‘I’ll come and get you.’
Next Male asthma deaths not dropping

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.